ESTRO 2025 - Abstract Book

S839

Clinical - Gynaecology

ESTRO 2025

Conclusion: The application of the EMBRACE-II-protocol 2,3 leads to predictable performance and results, with excellent and stable long-term disease outcome and very limited G4/5 morbidity. These results compare favorably with published trials. Therefore, EMBRACE-II represents the new standard of care in management of LACC.

Keywords: EMBRACE II, cervix cancer, overall results

References: 1. Pötter R, Tanderup K, Schmid MP, et al.; EMBRACE Collaborative Group. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort. Lancet Oncol. 2021 Apr;22(4):538 547. doi: 10.1016/S1470-2045(20)30753-1.